Richard Pelikan
About Richard Pelikan
Richard Pelikan is a Bioinformatics Scientist with extensive experience in computational analysis of proteomic data and autoimmune disorders. He currently works at the Oklahoma Medical Research Foundation and has a strong academic background from the University of Pittsburgh.
Work at Oklahoma Medical Research Foundation
Richard Pelikan has been employed as a Bioinformatics Scientist at the Oklahoma Medical Research Foundation since 2014. In this role, he focuses on the computational analysis of proteomic data and explores autoimmune disorders through high-throughput genomic and epigenomic assays. His work involves leveraging epigenetics and single-cell technologies to understand cell-specific genetic effects in these disorders. He also applies machine learning techniques to identify novel functional phenomena that contribute to autoimmunity.
Education and Expertise
Richard Pelikan holds a Doctor of Philosophy (PhD) in Intelligent Systems from the University of Pittsburgh, which he completed from 2005 to 2011. Prior to his PhD, he earned a Master of Science (MS) in Computer Science from the same institution, studying from 2002 to 2005. He also obtained a Bachelor of Science (BS) in Computer Science from the University of Pittsburgh, where he studied from 1998 to 2002. His educational background provides a strong foundation for his expertise in bioinformatics and computational analysis.
Background
Before joining the Oklahoma Medical Research Foundation, Richard Pelikan served as a Postdoctoral Research Associate at the University of Southern California from 2011 to 2014. He also worked as a Graduate Research Assistant at the University of Pittsburgh for nine years, from 2002 to 2011. His extensive experience in research and analysis has contributed to his current focus on autoimmune disorders and the application of advanced computational techniques.
Research Contributions
Richard Pelikan has contributed to significant research in the field of autoimmune diseases, particularly regarding the regulatory potential of hQTLs and important variants in lupus. His work emphasizes the use of high-throughput genomic and epigenomic assays to explore the complexities of autoimmune disorders. He consults on various projects at the Oklahoma University Health Sciences Center, further extending his impact in the field.